Puzo Michael J lessened its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,749 shares of the medical instruments supplier's stock after selling 1,416 shares during the quarter. Puzo Michael J's holdings in Becton, Dickinson and Company were worth $4,027,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of BDX. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB increased its holdings in Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock worth $39,951,000 after purchasing an additional 20,859 shares in the last quarter. Arete Wealth Advisors LLC bought a new position in Becton, Dickinson and Company in the third quarter valued at about $767,000. Busey Bank boosted its stake in shares of Becton, Dickinson and Company by 3.8% during the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock valued at $15,031,000 after purchasing an additional 2,399 shares in the last quarter. Finally, Centre Asset Management LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth about $8,382,000. Institutional investors own 86.97% of the company's stock.
Becton, Dickinson and Company Trading Down 1.8 %
Shares of Becton, Dickinson and Company stock traded down $3.60 on Wednesday, reaching $197.23. 1,086,426 shares of the company's stock were exchanged, compared to its average volume of 1,663,071. The company has a market capitalization of $56.63 billion, a P/E ratio of 32.67, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 52 week low of $193.14 and a 52 week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm's 50-day moving average is $227.28 and its two-hundred day moving average is $230.68.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.11%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.
Becton, Dickinson and Company declared that its board has initiated a stock repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.
Analyst Ratings Changes
BDX has been the topic of a number of research reports. StockNews.com raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Barclays decreased their price objective on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a report on Monday. Finally, Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Buy" and an average target price of $275.71.
Check Out Our Latest Report on BDX
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock in a transaction on Friday, January 17th. The shares were sold at an average price of $236.51, for a total transaction of $141,196.47. Following the transaction, the executive vice president now directly owns 5,544 shares of the company's stock, valued at $1,311,211.44. The trade was a 9.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard Byrd sold 459 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the sale, the executive vice president now owns 6,952 shares of the company's stock, valued at approximately $1,598,960. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,196 shares of company stock valued at $962,685 over the last three months. Corporate insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
